- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03364400
Phase 1 Study Evaluating VT1021 in Patients With Advanced Solid Tumors
A Phase 1 Study Evaluating the Safety, Pharmacology, and Preliminary Activity of VT1021 in Patients With Advanced Solid Tumors
Study Overview
Detailed Description
Study Type
Enrollment (Actual)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
Florida
-
Sarasota, Florida, United States, 34232
- Florida Cancer Specialists
-
-
Illinois
-
Chicago, Illinois, United States, 60611
- Northwestern Memorial Hospital
-
-
Indiana
-
Lafayette, Indiana, United States, 47905
- Horizon Oncology Center
-
-
Maryland
-
Baltimore, Maryland, United States, 21287
- The Johns Hopkins Hospital
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02114
- Massachusetts General Hospital
-
Boston, Massachusetts, United States, 02115
- Dana Farber Cancer Institute
-
Boston, Massachusetts, United States, 02215
- Beth Israel
-
-
Ohio
-
Cleveland, Ohio, United States, 44195
- Cleveland Clinic
-
Cleveland, Ohio, United States, 44106
- Case Western Reserve University
-
-
Oklahoma
-
Oklahoma City, Oklahoma, United States, 73104
- University of Oklahoma
-
-
Texas
-
Houston, Texas, United States, 77030
- MD Anderson Cancer Center
-
San Antonio, Texas, United States, 78229
- START
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
Dose Escalation Phase:
Patients must be refractory to, or intolerant of, existing therapies known to provide clinical benefit for their condition (i.e., cancer diagnosis)
Dose Expansion Phase:
Ovarian:
Patients with confirmed diagnosis of unresectable epithelial ovarian, fallopian tube, or primary peritoneal cancer must have received ≤ 3 prior lines of therapy in a platinum resistant setting. BRCA mutant patients are excluded unless they have failed previous line with a PARP inhibitor
Pancreatic:
Patients with confirmed diagnosis of pancreatic cancer must have received ≤2 prior lines of therapy
Triple Negative Breast Cancer:
Patients with confirmed diagnosis of metastatic TNBC must have received ≤ 3 prior lines of therapy for metastatic disease
Glioblastoma:
Patients with confirmed relapsed or refractory glioblastoma must have received ≤2 prior lines of systemic therapy
CD36-high basket cohort:
Patients with solid tumor cancers that have high expression of CD36 by immunohistochemistry. Patients must have received ≤ 3 prior lines of therapy for metastatic disease
- Patient has evaluable disease by RECIST v1.1
- Patient has a performance status (PS) of 0-2 on the Eastern Cooperative Oncology Group (ECOG) scale
- Patient is at least 21 days (12 weeks for glioblastoma patients) removed from therapeutic radiation or chemotherapy prior to the first scheduled day of dosing with VT1021
- Patient has adequate organ function
- Patient agrees to use acceptable methods of contraception during the study and 60 days after the last dose of VT1021
Exclusion Criteria:
- Diagnosis of another malignancy within the past 2 years (excluding a history of carcinoma in situ of the cervix, superficial non-melanoma skin cancer, superficial bladder cancer, or endometrial cancer that has been adequately treated, or stage 1 prostate cancer that does not require treatment)
- History of a major surgical procedure or a significant traumatic injury within 14 days prior to commencing treatment, or the anticipation of the need for a major surgical procedure during the course of the study
- Treatment with investigational therapy(ies) within 5 half-lives of the investigational therapy prior to the first scheduled day of dosing with VT1021, or 4 weeks if the half-life of the investigational agent is not known
- Concurrent serious (as determined by the Principal Investigator) medical conditions, including, but not limited to, New York Heart Association (NYHA) class III or IV congestive heart failure, history of congenital prolonged QT syndrome, uncontrolled infection, active hepatitis B, hepatitis C or HIV, or other significant co-morbid conditions that, in the opinion of the Investigator, would impair study participation or cooperation
- Pregnancy or lactation
- Evidence of symptomatic brain metastases. Patients with treated (surgically excised or irradiated) and stable brain metastases are eligible, assuming the patient has adequately recovered from treatment
- Other concurrent chemotherapy, immunotherapy, radiotherapy or investigational therapy
- Requirement to palliative radiotherapy to lesions that are defined as target lesions by RECIST criteria at the time of study entry
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Sequential Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: VT1021
Escalating doses of VT1021 to determine RP2D
|
Peptide
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Identify recommended phase 2 dose by measuring incidence of dose limiting toxicities at increasing dose levels. Determine the safety and tolerability of VT1021 in ovarian, pancreatic, triple negative breast cancer, glioblastoma and CD36 high cohort.
Time Frame: 2 doses weekly for 4 week cycle
|
Increasing dose levels until RP2D determined.
|
2 doses weekly for 4 week cycle
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
To characterize the adverse event profile of VT1021 monotherapy as measured by CTCAE v 5.0 in subjects with advanced solid tumors.
Time Frame: 2 doses weekly for 4 week cycle
|
To characterize the type, frequency and severity of the adverse events of VT1021 monotherapy determined by CTCAE v 5.0
|
2 doses weekly for 4 week cycle
|
To analyze the serum/plasma levels collected from patients for concentrations of VT1021 using non-compartmental analysis to estimate the pharmacokinetic parameter of Cmax
Time Frame: 2 cycles of 2 doses weekly for 4 week cycle
|
The pharmacokinetics of VT1021 will be measured on specified days during Cycle 1 and Cycle 2
|
2 cycles of 2 doses weekly for 4 week cycle
|
To analyze the serum/plasma levels collected from patients for concentrations of VT1021 using non-compartmental analysis to estimate the pharmacokinetic parameter of Tmax
Time Frame: 2 cycles of 2 doses weekly for 4 week cycle
|
The pharmacokinetics of VT1021 will be measured on specified days during Cycle 1 and Cycle 2
|
2 cycles of 2 doses weekly for 4 week cycle
|
To analyze the serum/plasma levels collected from patients for concentrations of VT1021 using non-compartmental analysis to estimate the pharmacokinetic parameter of AUC0-t
Time Frame: 2 cycles of 2 doses weekly for 4 week cycle
|
The pharmacokinetics of VT1021 will be measured on specified days during Cycle 1 and Cycle 2
|
2 cycles of 2 doses weekly for 4 week cycle
|
To analyze the serum/plasma levels collected from patients for concentrations of VT1021 using non-compartmental analysis to estimate the pharmacokinetic parameter of AUC0-∞
Time Frame: 2 cycles of 2 doses weekly for 4 week cycle
|
The pharmacokinetics of VT1021 will be measured on specified days during Cycle 1 and Cycle 2
|
2 cycles of 2 doses weekly for 4 week cycle
|
To analyze the serum/plasma levels collected from patients for concentrations of VT1021 using non-compartmental analysis to estimate the pharmacokinetic parameters of the terminal elimination of half-life
Time Frame: 2 cycles of 2 doses weekly for 4 week cycle
|
The pharmacokinetics of VT1021 will be measured on specified days during Cycle 1 and Cycle 2
|
2 cycles of 2 doses weekly for 4 week cycle
|
To analyze the serum/plasma levels collected from patients for concentrations of VT1021 using non-compartmental analysis to estimate the pharmacokinetic parameters of clearance, volume of distribution at steady state (Vdss)
Time Frame: 2 cycles of 2 doses weekly for 4 week cycle
|
The pharmacokinetics of VT1021 will be measured on specified days during Cycle 1 and Cycle 2
|
2 cycles of 2 doses weekly for 4 week cycle
|
To determine preliminary evidence of efficacy of VT1021 monotherapy
Time Frame: Through study completion, an average of 1 year
|
Using objective response rate based on RECIST v1.1 and RANO
|
Through study completion, an average of 1 year
|
To determine preliminary evidence of efficacy of VT1021 monotherapy
Time Frame: Through study completion, an average of 1 year
|
Using disease control rate
|
Through study completion, an average of 1 year
|
To determine preliminary evidence of efficacy of VT1021 monotherapy
Time Frame: Through study completion, an average of 1 year
|
Using progression free survival based on RECIST v1.1 and RANO
|
Through study completion, an average of 1 year
|
To determine overall response rate by iRECIST
Time Frame: Through study completion, an average of 1 year
|
Using radiographic imaging assessment of disease
|
Through study completion, an average of 1 year
|
Collaborators and Investigators
Sponsor
Investigators
- Study Director: Judy Chaio, MD, Medical Director
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- VT1021-01
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Solid Tumor
-
Memorial Sloan Kettering Cancer CenterRecruitingSolid Tumor | Solid Tumor, Adult | Solid Tumor, Unspecified, AdultUnited States
-
Memorial Sloan Kettering Cancer CenterLincoln Medical and Mental Health CenterRecruitingSolid Tumor | Solid Tumor, Adult | Solid Tumor, Unspecified, AdultUnited States, Puerto Rico
-
Memorial Sloan Kettering Cancer CenterLincoln Medical and Mental Health CenterRecruitingSolid Tumor | Solid Tumor, Adult | Solid Tumor, Unspecified, AdultUnited States, Puerto Rico
-
Aadi Bioscience, Inc.RecruitingAdvanced Solid Tumor | Tumor | Tumor, SolidUnited States
-
RemeGen Co., Ltd.CompletedMetastatic Solid Tumor | Locally Advanced Solid Tumor | Unresectable Solid TumorAustralia
-
Sorrento Therapeutics, Inc.WithdrawnSolid Tumor | Relapsed Solid Tumor | Refractory Tumor
-
Impact Therapeutics, Inc.RecruitingSolid Tumor | Advanced Solid TumorChina, Taiwan, United States, Australia
-
Partner Therapeutics, Inc.WithdrawnSolid Tumor | Solid Tumor, AdultUnited States
-
Shenzhen Ionova Life Sciences Co., Ltd.Merck Sharp & Dohme LLCRecruitingCancer | Solid Tumor, Adult | Solid Carcinoma | Solid Tumor, Unspecified, Adult | Cancer Metastatic | Tumor, SolidUnited States
-
BeiGeneRecruitingSolid Tumor | Advanced Solid TumorUnited States, New Zealand, Australia, China
Clinical Trials on VT1021
-
Global Coalition for Adaptive ResearchBayer; Kazia Therapeutics Limited; Biohaven Pharmaceuticals, Inc.; Kintara Therapeutics... and other collaboratorsRecruitingGlioblastomaUnited States, France, Germany, Canada, Australia, Switzerland